// App-Quantinova.ai

8011 : Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.

Researchers

Presenter

  • Ray Comenzo

Principal Investigators

  • Efstathios Kastritis

  • Mathew Maurer

  • Jeffrey A. Zonder

  • Monique Minnema

  • Stefan Schonland

  • Ashutosh Wechalekar

  • Giovanni Palladini

  • Xiang Qin

  • Sandra Y. Vasey

  • Imran Khan

  • Jordan Mark Schecter

  • Giampaolo Merlini

Medical Centers

  • Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece

  • Presbyterian Hospital and Vanderbilt Clinic, New York, NY

  • Barbara Ann Karmanos Cancer Institute, Detroit, MI

  • Department of Hematology, UMC Utrecht Cancer Center, Utrecht, Netherlands

  • Heidelberg University Hospital, Heidelberg, Germany

  • University College London and the Royal Free London NHS Foundation Trust, London, United Kingdom

  • Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Scientific Institute Policlinico San Matteo, University of Pavia, Pavia, Italy

Locations

  • Greece

  • Italy

  • Netherlands

  • Germany

  • United Kingdom

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Hyaluronidase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

  • rHuPH20

  • Sparsentan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT03201965

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved